Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine.
Alleva DG, Feitsma EA, Janssen YF, Boersma HH, Lancaster TM, Sathiyaseelan T, Murikipudi S, Delpero AR, Scully MM, Ragupathy R, Kotha S, Haworth JR, Shah NJ, Rao V, Nagre S, Ronca SE, Green FM, Shaw SA, Aminetzah A, Kruijff S, Brom M, van Dam GM, Zion TC.
Alleva DG, et al. Among authors: kruijff s.
NPJ Vaccines. 2024 Feb 21;9(1):40. doi: 10.1038/s41541-024-00830-2.
NPJ Vaccines. 2024.
PMID: 38383578
Free PMC article.